Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications - Loganathan, Subramanian; Athalye, Sandeep N.; Joshi, Shashank R. (Expert opinion on biological therapy, 2020)
Keywords: Anti-CD6; Antibodies, Monoclonal, Humanized - pharmacology; Antibodies, Monoclonal, Humanized - therapeutic use; Antigens, CD - immunology; Antigens, Differentiation, T-Lymphocyte - immunology; Betacoronavirus; Cell Differentiation - drug effects; Cell Differentiation - physiology; Cell Proliferation - drug effects; Cell Proliferation - physiology; Coronavirus Infections - drug therapy; Coronavirus Infections - immunology; COVID-19; cytokine storm; Cytokines - antagonists & inhibitors; Cytokines - immunology; Humans; inflammatory; Itolizumab; Lymphocyte Activation - drug effects; Lymphocyte Activation - physiology; monoclonal antibodies; Pandemics; plaque psoriasis; Pneumonia, Viral - drug therapy; Pneumonia, Viral - immunology; SARS-CoV-2; T-Lymphocytes - drug effects; T-Lymphocytes - immunology; Treatment Outcome; COVID-19; Anti-CD6; Itolizumab; cytokine storm; inflammatory; plaque psoriasis; monoclonal antibodies